ReachMD

Episodes 1-9 of 9

• • 

    

    Kevan C. Herold, MD

    Peer

  • 

    

    Andrea Steck, MD

    Peer

  • 

    

    Anette Gabriele Ziegler, MD

    Peer

  0

  

  RestartResume

  Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy -

  Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

  Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy -

  Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

  0.50 credits

• • 

    

    Kevan C. Herold, MD

    Peer

  • 

    

    Stephen Gitelman, MD

    Peer

  2

  

  RestartResume

  Changing Treatment Paradigms in Type 1 Diabetes: Role of Anti-CD3 Targeted Therapy -- Anti-CD3 Monoclonal Antibodies to Prevent/Delay Onset of Type 1 Diabetes

  Changing Treatment Paradigms in Type 1 Diabetes: Role of Anti-CD3 Targeted Therapy -- Anti-CD3 Monoclonal Antibodies to Prevent/Delay Onset of Type 1 Diabetes

  0.50 credits

• • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  • 

    

    James A. Underberg, MD

    Peer

  • 

    

    Nathan D. Wong, PhD, MPH

    Peer

  3

  

  RestartResume

  Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

  Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

  0.50 credits

• • 

    

    Christina Y. Weng, MD, MBA

    Peer

  • 

    

    Arshad M. Khanani, MD, MA

    Peer

  3

  

  RestartResume

  Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

  Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

  0.25 credits

• • 

    

    Vivian Fonseca, MD, FRCP

    Peer

  • 

    

    Rishi P. Singh, MD

    Peer

  4

  

  RestartResume

  Frontiers in Diabetic Macular Edema: Addressing Health Disparities and Other Barriers to Optimal Outcomes

  Frontiers in Diabetic Macular Edema: Addressing Health Disparities and Other Barriers to Optimal Outcomes

  0.25 credits

• • 

    

    Kevan C. Herold, MD

    Peer

  • 

    

    Chantal Mathieu, MD, PhD

    Peer

  2

  

  RestartResume

  Type 1 Diabetes & the Role of Anti-CD3 Targeted Therapy

  Type 1 Diabetes & the Role of Anti-CD3 Targeted Therapy

  0.50 credits

• • 

    

    Janet B. McGill, MD, MA, FACE, FACP

    Peer

  • 

    

    John J. Russell, MD

    Peer

  14

  

  RestartResume

  At the Crossroad of Care: New Advances in Diabetic Kidney Disease

  At the Crossroad of Care: New Advances in Diabetic Kidney Disease

  0.50 credits

• • 

    

    Eliot Brinton, MD, FAHA, FNLA

    Peer

  • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  21

  

  RestartResume

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  0.75 credits

• • 

    

    Christopher P. Cannon, MD

    Peer

  • 

    

    Samuel Dagogo-Jack, MD, DSc

    Peer

  12

  

  RestartResume

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  0.25 credits